<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345644</url>
  </required_header>
  <id_info>
    <org_study_id>HMR4003B_3507</org_study_id>
    <secondary_id>EudraCT # :2005-005598-30</secondary_id>
    <nct_id>NCT00345644</nct_id>
  </id_info>
  <brief_title>Risedronate in Osteopenic Postmenopausal Women</brief_title>
  <acronym>OSMAUSE</acronym>
  <official_title>A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 24 Month, Monocenter Study Comparing Weekly Oral Risedronate 35 mg and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare risedronate 35 mg and placebo with respect
      to the percent change at 12 months for distal radius trabecular bone volume (BV/TV) in
      osteopenic postmenopausal women, as measured by three-dimensional peripheral quantitative
      computed tomography (3D pQCT).

      The secondary objectives are to compare the percent change from Screening/Baseline between
      the 2 treatment groups for the following measurements:

        -  Bone mineral density of the lumbar spine, femoral neck, femoral trochanter, and total
           proximal femur using a dual energy X-ray absorptiometry (DXA) scan at 12 and 24 months;

        -  3D pQCT analysis of distal radius and distal tibia bone microarchitecture data at 6, 12,
           and 24 months; and

        -  Bone turnover markers (BTMs) of:

             -  fasting serum carboxyterminal cross linking telopeptide of type 1 bone collagen
                (CTX 1);

             -  serum aminoterminal propeptide of type 1 procollagen (PINP); and

             -  urine N-telopeptide cross-links (NTX) at 3, 6, 12, and 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy data : 3-D-pQCT Data—Microarchitectural Parameters (Distal Radius BV/TV Measurements)</measure>
    <time_frame>BV/TV percent change from Baseline at distal radius as measured in the non dominant wrist at Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance data :collection of AEs, with special interest for upper gastrointestinal (UGI) AEs and clinical fractures</measure>
    <time_frame>at all visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>risedronate sodium 35 mg tablets (once a week dose)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate placebo</intervention_name>
    <description>placebo for risedronate tablets (once a week dose)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteopenic, postmenopausal women, between 55 and 75 years of age with a body mass
             index (BMI) &lt; 30 kg/m²

        Exclusion Criteria:

          -  Clinical or radiological evidence of osteoporosis

          -  Severe renal impairment

          -  Serum 5-hydroxy vitamin D level &lt; 15 ng/ml

          -  History of recent primary hyperparathyroidism or recent thyroid disorder

          -  History of any generalized bone disease

          -  Current use of glucocorticoids, estrogens, progestins, calcium supplements &gt; 1 g/day,
             vitamin D supplements &gt; 800 IU/day, parathyroid hormone (PTH), or any bisphosphonate
             for &gt; 1 month at any time within the past 6 months.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie SEBILLE, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2006</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

